Tepotinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 225 mg
Reference Brands: Tepmetko (USA/EU)
Category:
Oncology Cancer Care
Tepotinib is available in Tablets
and strengths such as 225 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tepotinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tepotinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tepotinib is an oral anticancer medication sold under the brand name Tepmetko, used for the treatment of non-small cell lung cancer (NSCLC) in adults. It is specifically indicated for patients with metastatic NSCLC whose tumors harbor a mutation that leads to MET exon 14 skipping, a genetic alteration that drives cancer cell growth and survival.
Tepotinib works as a selective inhibitor of the MET receptor tyrosine kinase. By blocking MET signaling, it interferes with pathways that promote tumor cell proliferation, survival, and metastasis. This targeted mechanism allows for precision therapy in patients whose cancers are driven by MET exon 14 alterations. Tepotinib provides a valuable treatment option for adults with this specific form of NSCLC, offering an alternative for patients who may not respond to conventional chemotherapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing